By Dave Andrusko
Under the “you can always find a judge category,” U.S. District Judge Theodore Chuang in Maryland gave the Abortion Industry its heart’s desire today.
In an 80-page decision, the Obama nominee “agreed Monday to suspend a rule that requires women during the COVID-19 pandemic to visit a hospital, clinic or medical office to obtain an abortion pill,” Michael Kunzelman of the Associated Press reported. “Chuang’s ruling will allow healthcare providers to arrange for mifepristone to be mailed or delivered to patients during the public health emergency declared by the secretary of the U.S. Department of Health and Human Services.”
Mifepristone is one of the two-drugs that make up the RU-486 (or “medication abortion”) technique. The other is misoprostol.
We wrote about this suit being filed back in early June. It was brought by the ACLU on behalf of the American College of Obstetricians and Gynecologists (ACOG) and other pro-abortion groups.
As NRL News Today has reported on multiple occasions, the Abortion Industrial Media Complex (AIMC) never ceases to whine about how pro-lifers are supposedly “exploiting” the pandemic. How are we supposedly doing so? Because some governors commonsensically would not allow non-essential surgeries, including elective abortions, during this medical emergency.
Meanwhile, the AIMC never tires of trying to find ways to circumvent rules and regulations intended to protect women so as to expand the number of ways unborn babies can be killed.
The #1 short-term objective with massive long-term implications is “Do-it-Yourself” chemically-induced abortions performed at home. Proponents brush off how dangerous this is to women in the rush to exploit the current pandemic.
Without rehashing the long history, the truth is that at one point in time there were more restrictions on mifepristone/misoprostol, all of which made sense. The Abortion Industry, over time, decided to simply ignore them and during the Obama Administration, the FDA eventually partially gave in.
But the FDA has held firm on what’s called a “risk evaluation and mitigation strategy.” Under R.E.M.S. (as the New York Times observed unhappily) “mifepristone can be dispensed only in clinics, medical offices and hospitals; only by, or under the supervision of, a doctor certified to prescribe the drug; and only to patients who have signed an F.D.A.-approved patient agreement.”
And as always, we’re told none of these safeguards is necessary.
Judge Chuang bought it, hook, line, and sinker.
“Particularly in light of the limited timeframe during which a medication abortion or any abortion must occur, such infringement on the right to an abortion would constitute irreparable harm,” Judge Chuang wrote.
As noted, the FDA has refused to grow lax in protecting women. It is supported in its stand by pro-life elected officials and pro-life organizations, such as National Right to Life.
In a letter sent to FDA Commissioner Stephen Hahn, M.D., thirty-eight Senators and 121 Representatives urged “robust enforcement” of the REMS involving the mifepristone abortion-drug process. The members of Congress wrote,
Despite claims that medication abortion is safe and easy, research proves that as many as five to seven percent of women who take abortion drugs will require follow-up surgery, and three percent could end up in the emergency room. Self-managed abortions from home are especially dangerous; in fact, half of abortion providers do not consider them safe, according to a 2019 survey published in the journal Contraception. Further, medication abortion becomes even more dangerous in situations where women cannot access emergency medical care. This is especially concerning during the COVID-19 pandemic as emergency rooms are currently being overwhelmed.